Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatugvedotin + Gemcitabine in Second-line Advanced PDAC
NCT07685470Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2026
- Primary completion
- May 2028
01
Overview
A Phase 2 trial of cofetuzumab pelidotin in pancreatic ductal adenocarcinoma (PDAC), sponsored by Peking Union Medical College Hospital. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
cofetuzumab pelidotin
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07685470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07685470.